Back

Novel microRNA multivariate biomarkers of response to immunotherapy against HPV E6 oncogene

Fleeman, R. M.; Deiter, G.; Lambert, K.; Proctor, E. A.; Phaeton, R.

2020-06-28 systems biology
10.1101/2020.06.26.174441 bioRxiv
Show abstract

Cervical cancer is caused by the persistent infection high-risk types of human papillomavirus (HPV) in over 99.9% of cases. To favor malignant transformation, HPV E6 and E7 oncogenes disrupt both p53 and retinoblastoma (Rb) respectively and control microRNA (miR) networks. We have previously demonstrated the therapeutic potential of anti-HPV E6 monoclonal antibodies (mAbs) in experimental models of human cervical cancer; yet the underlying mechanism remains unclear. Here, we sought to determine if anti-HPV E6 mAbs modulate the miR signatures of HPV E6 oncogenes. To this end, we performed qRT-PCR to measure the expression of thirty-four miRs and found that univariate analysis is not able to identify novel interactions characteristic of complex biological systems. Thus, we utilized partial least squares discriminant analysis (PLSDA) to identify signatures of co-varying miRs specific to mAb treatment. These miR signatures predictively discriminate between anti-HPV E6 mAb response and control mAb treatment, which may provide mechanistic insight into the action of anti-HPV E6 mAbs.Competing Interest StatementThe authors have declared no competing interest.View Full Text

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.